Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1Breast 1

Conditions

Diabetes Mellitus, Type 2 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Hyperglycemia 1Breast Neoplasms 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2384Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1831Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1016Vincristine 964Cetuximab 945Trastuzumab 944Prednisone 941Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Vildagliptin × Clear all
NCT04300790 2025-07-29

METALLICA

MedSIR

Phase 2 Completed
69 enrolled
BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT02475499 2016-03-14

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
886,172 enrolled
Gastrointestinal

Diabetes Mellitus, Type 2, Pancreatic Neoplasms

NCT01588587 2012-10-19

DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients

Nagaoka Red Cross Hospital

Unknown
500 enrolled

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡